Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 6, 118 (2000)
doi:10.1038/72181
Biotechnology industry responds to gene therapy death
Helen Commander1
- London
The notoriously fickle biotechnology company investment community has hedged its bets on the issue of gene therapy. Following the death last fall of Arizona teenager Jesse Gelsinger and the ensuing federal investigation into this experimental technique, (Nature Med. 6, 6; 2000
To read this story in full you will need to login or make a payment (see right).
